Therapeutic options for diseases due to potential viral agents of bioterrorism.

Abstract

The etiologic agents of smallpox and viral hemorrhagic fever have emerged as potential agents of bioterrorism due to their virulence, potential for human to human dissemination and limited strategies for treatment and prevention. Cidofovir has shown significant promise in animal models, and limited case reports in humans are encouraging. Ribavirin is the treatment of choice for certain hemorrhagic fever viral infections, but has no current application to Ebola and Marburg infections. Current vaccine strategies for smallpox are effective, but carry significant risk for complications. Licensed vaccines for hemorrhagic fever viruses are limited to yellow fever, but animal studies are promising. Genomic analysis of the viral pathogen and the animal model response to infection may provide valuable information enabling the development of novel treatment and prevention strategies. Current knowledge of these strategies is reviewed.

• Authors: Michael S Bronze, Ronald A Greenfield
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 4 Issue 2 Pg. 172-8 (Feb 2003) ISSN: 1472-4472 [Print] England
• PMID: 12669378 (Publication Type: Journal Article, Review)

Chemical References

• Antiviral Agents

Topics

• Antiviral Agents (therapeutic use)
• Bioterrorism
• Hemorrhagic Fevers, Viral (therapy)
• Humans
• Immunotherapy
• Smallpox (therapy)
• Vaccination
• Virus Diseases (drug therapy, prevention & control, therapy, virology)